YARW Yarrow Bioscience, Inc. - Common Stock

$41.26
Price · Aug 19, 2026
Fundamentals as of Aug 13, 2026

YARW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$41.26
Market Cap
P/E (TTM)
EPS (TTM)
Revenue (TTM)
Div Yield
ROE
Debt/Equity
52W Range
$26 – $44

YARW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income
EPS
Free Cash Flow
Margins

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
YARW
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
YARW
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
YARW
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
YARW
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
YARW
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
YARW
Peer Median

Dividends Yield, payout ratio, dividend history, 5Y CAGR

Dividend Yield
Payout Ratio
5Y Div CAGR
Ex-dateAmount
July 24, 2026$20.1000

YARW Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

2 analysts · 2026-08-15
Median target $57.00 +38.1%
Mean target $57.00 +38.1%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
4.4%
Period EPS Actual EPS Est Surprise
March 31, 2026 $-4.00 $-9.18 5.2%
Dec. 31, 2025 $-5.65 $-9.18 3.5%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Company insiders 2 insiders · 2 officers · 1 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
David Domzalski President and CEO March 17, 2022 A 1,072,935 0 0 $0
Mutya Harsch Chief Legal Officer and GC April 6, 2020 F 170,712 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 1 position

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
ORBIMED ADVISORS LLC, OrbiMed Capital GP X LLC, OrbiMed Capital GP X, LP, OrbiMed Genesis GP LLC Aug. 5, 2026 9.97% Initial filing SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.